JAK Inhibitors 'may Prove Useful' in Wider Range of Immune-mediated Inflammatory

摘要

There are also additional concerns that venous thromboembolism may be a class effect in JAK inhibitors, although Vleugels said that the data on this is "somewhat lacking at this time." Compared to TNF alpha inhibitors, researchers believe JAK inhibitors demonstrate lower risks for tuberculosis reactivation and serious infection, but with a higher potential risk for malignancy."Looking forward, JAK inhibitors may prove useful in an even wider array of conditions," Vleugels said. "Currently, we have FDA approvals for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and polyarticular juvenile idiopathic arthritis. We know there is a clear signal for zoster in patients with JAK inhibition. We know there is an increased thromboembolism risk in patients treated with tofacitinib for rheumatoid arthritis."